Home » Stocks » LYEL

Lyell Immunopharma, Inc. (LYEL)

Stock Price: $16.60 USD -0.06 (-0.36%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
Market Cap 4.03B
Revenue (ttm) 8.95M
Net Income (ttm) -230.28M
Shares Out 242.83M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 22
Last Price $16.60
Previous Close $16.66
Change ($) -0.06
Change (%) -0.36%
Day's Open 16.74
Day's Range 16.00 - 16.88
Day's Volume 486,044
52-Week Range 14.99 - 18.90

News

Hide News

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with ...

6 days ago - GlobeNewsWire

Lyell Immunopharma, Inc. has filed to go public with an IPO on the NASDAQ.

4 weeks ago - SEC

About LYEL

Lyell Immunopharma is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. We believe the key to effective cell therapy is the mastery of the identity, fate and function of cells to create living medicines. We take a systematic, interrogative, cell biology-driven approach to overcome what we view as the two major barriers to successful ACT – (1) T cell exhaustion and (2) lack of durable stemness – through the application of our proprietary genetic and epigenetic reprogramming technologies, G... [Read more...]

Industry
Biotechnology
IPO Date
Jun 17, 2021
CEO
Elizabeth Homans
Employees
188
Stock Exchange
NASDAQ
Ticker Symbol
LYEL
Full Company Profile

Financial Performance

In 2020, LYEL's revenue was $7.76 million, an increase of 1,080.52% compared to the previous year's $657,000. Losses were -$204.47 million, 58.0% more than in 2019.

Financial Statements